CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 1,040 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 1,040 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total value of $51,230.40. Following the sale, the general counsel directly owned 95,857 shares of the company’s stock, valued at approximately $4,721,915.82. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $51.52 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The stock’s fifty day simple moving average is $55.07 and its 200 day simple moving average is $53.24. CRISPR Therapeutics AG has a 52-week low of $44.12 and a 52-week high of $75.06.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The company had revenue of $10.18 million for the quarter. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -4.48 earnings per share for the current year.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently made changes to their positions in the stock. Versant Capital Management Inc boosted its holdings in shares of CRISPR Therapeutics by 175.1% during the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after purchasing an additional 296 shares during the period. Ameritas Advisory Services LLC purchased a new position in CRISPR Therapeutics during the second quarter valued at approximately $56,000. GAMMA Investing LLC increased its stake in CRISPR Therapeutics by 92.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock valued at $69,000 after buying an additional 597 shares during the period. Hollencrest Capital Management increased its stake in CRISPR Therapeutics by 249.9% in the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock valued at $62,000 after buying an additional 937 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its position in CRISPR Therapeutics by 184.2% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,637 shares of the company’s stock worth $89,000 after buying an additional 1,061 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. UBS Group started coverage on CRISPR Therapeutics in a research note on Thursday. They issued a “neutral” rating and a $52.00 price target on the stock. Citizens Jmp reiterated a “market outperform” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.75.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.